The company will be represented on the NCR board by its US chief executive officer Oludare Odumosu MPH, Ph.D.
NCR is a non-partisan advocacy group focusing on federal cannabis reform in the US.
As part of its reform agenda, it is seeking to remove federal restrictions that prohibit medical research involving cannabis and to allow companies to operate legally in the US-based cannabis industry.
Excited to have Zelira
Zelira's US CEO Oludare Odumosu.
Trulieve chief executive officer and NCR board of directors second vice chair Kim Rivers said: “We are excited to have Zelira join our growing roundtable.
“Their focus on research and health is ground-breaking and will help us really show the breadth and potential of the cannabis industry”.
Bringing breakthrough therapeutics to market
Dr Odumosu said: “The manner that the federal government handles reform will have fundamental impacts on the people we serve.
"Our company is committed to bringing breakthrough therapeutics to market and we need to have the regulatory framework that will allow the research to expand and grow on a Federal/National level."
NCR first vice-chair Chanda Macias said: “I have worked extensively with Dr Odumosu and his colleagues at Zelira Therapeutics.
”I am personally thrilled that he will be joining us at the table in Washington.
“His biopharmaceutical expertise will be invaluable as my colleagues and I work to expand access to clinically proven cannabis medicines for patients around the country while also addressing important issues of reform at the federal level.
The honorary chairman of the NCR is John Boehner, the former Speaker of the US Congress.
In addition, the roundtable announced the appointment of a new honorary co-chair, Kathleen Sebelius, who is the former governor of Kansas and former Human Services Secretary, under former President Barack Obama.